IBRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- ImmunityBio reports Phase 3 data showing 84% cystectomy avoidance at three years and complete responses lasting beyond 53 months with ANKTIVA plus BCG in BCG-unresponsive NMIBC with CIS, with or without papillary tumorsOct 16, 2026
- FDA expands ANKTIVA approval for BCG-unresponsive non-muscle-invasive bladder cancer to include both papillary disease and carcinoma in situ (CIS)Oct 14, 2026
- ImmunityBio received UAE marketing authorization for ANKTIVA across multiple bladder cancer indications and metastatic non-small cell lung cancerJul 31, 2026
- ImmunityBio presents analysis showing ANKTIVA plus BCG delivers lower treatment costs versus TAR-200 in NMIBC CISMay 23, 2026
- FDA accepts supplemental BLA for ANKTIVA plus BCG in bladder cancer with PDUFA date set for January 2027May 20, 2026